Lundbeck seeks partners on Alzheimer's drug after EMA rejection

The European Medicines Agency rejected Acrescent, Lundbeck's combination Alzheimer's treatment, last week, but the Scandinavian drugmaker is already moving forward with a next-generation treatment for the same ailment. Lundbeck is in the middle stages of development for AE58054, and the company is in search of partners to help develop the treatment, a spokesman told Bloomberg. Report

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.